«

»

Jun 14

Abbott to Acquire Visiogen.

The unique design of the Synchrony lens is made to mimic the eye’s natural capacity to change focus , with the potential to deliver a full selection of eyesight. Synchrony provides been implanted in more than 1,200 eye and provides been the main topic of extensive clinical research both in the U.S. And internationally. Synchrony has received CE tag designation and offers been available commercially in Europe since January 2009. It really is currently under review by the U also.S. Food and Drug Administration . ‘Visiogen’s Synchrony lens enables Abbott Medical Optics to enter the growing accommodating IOL segment and enhances our premium IOL portfolio which includes the Tecnis Multifocal zoom lens,’ said Jim Mazzo, senior vice president, Abbott, and president, Abbott Medical Optics.Infants in the lower-focus on group had a substantial decrease in the rate of treatment for retinopathy of prematurity, a finding that is consistent with the full total outcomes of trials conducted in the 1950s1 and SUPPORT.6,11 Because treatment for this condition is normally effective, blindness was rare, with similar rates in both target groupings in SUPPORT.11 However, retinopathy of prematurity causes various other structural and functional vision abnormalities that can be visually disabling,14 and these may become more common if the reported survival benefit with an increased oxygen saturation influences scientific practice.